MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
Adverum Biotechnologies Market Cap 2011-2025 | ADVM
As of December 15, 2025 Adverum Biotechnologies has a market cap of $ 86.2 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Adverum Biotechnologies
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 76.4 M | 17.8 M | 77.4 M | 173 M | 790 M | 666 M | 186 M | 347 M | 103 M | 155 M | 903 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 903 M | 17.8 M | 318 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
445 M | $ 4.86 | 3.08 % | $ 807 M |  Canada |
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aclaris Therapeutics
ACRS
|
152 M | $ 3.22 | -1.08 % | $ 249 M |  USA |
 |
AlloVir
ALVR
|
49 M | - | 4.14 % | $ 49.1 M | USA |
 |
Aptevo Therapeutics
APVO
|
889 K | $ 1.05 | -7.08 % | $ 290 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.16 B | $ 0.27 | -4.88 % | $ 588 M |  Israel |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
Catalyst Biosciences
CBIO
|
33.6 M | $ 13.58 | -3.62 % | $ 894 M | USA |
 |
Ascendis Pharma A/S
ASND
|
7.37 B | $ 216.09 | -1.96 % | $ 5 B |  Danmark |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alterity Therapeutics Limited
ATHE
|
895 M | $ 3.14 | -4.15 % | $ 7.55 B |  Australia |
 |
Celldex Therapeutics
CLDX
|
1.31 M | $ 27.1 | -1.51 % | $ 1.75 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
6.55 B | $ 88.16 | 0.19 % | $ 9.1 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
2.44 B | $ 24.27 | 2.75 % | $ 2.87 B | USA |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M |  France |
 |
CureVac N.V.
CVAC
|
3.53 B | $ 5.02 | -0.59 % | $ 934 M | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
BioVie
BIVI
|
2.44 M | $ 1.4 | -3.45 % | $ 2.07 M | USA |
 |
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
2.05 B | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
62.9 B | $ 93.87 | -0.99 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
1.73 B | $ 10.8 | - | $ 1.4 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
664 K | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.31 B | $ 26.2 | 3.68 % | $ 1.27 B | USA |
 |
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | USA |
 |
Anika Therapeutics
ANIK
|
373 M | $ 9.57 | 0.1 % | $ 140 M | USA |
 |
Eton Pharmaceuticals
ETON
|
114 M | $ 15.96 | -4.42 % | $ 409 M | USA |
 |
Evogene Ltd.
EVGN
|
66.3 M | $ 1.07 | -0.51 % | $ 27.9 M | Israel |
 |
Exelixis
EXEL
|
9.51 B | $ 41.43 | 1.35 % | $ 12 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
5.65 B | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
364 M | - | 3.77 % | $ 22.4 M | USA |
 |
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | USA |
 |
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
56.3 M | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
39.8 B | $ 548.8 | -2.74 % | $ 41.6 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | Israel |
|
Foghorn Therapeutics
FHTX
|
250 M | $ 4.36 | -1.8 % | $ 239 M | USA |
 |
Aytu BioScience
AYTU
|
15.8 M | $ 2.39 | 3.91 % | $ 15 M | USA |
 |
AstraZeneca PLC
AZN
|
81.2 B | $ 91.03 | 1.34 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
11.4 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
2.09 B | $ 8.85 | -1.72 % | $ 1.45 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
8.59 B | $ 11.36 | -1.47 % | $ 735 M | USA |
 |
Biogen
BIIB
|
19.3 B | $ 174.34 | 0.14 % | $ 25.4 B | USA |